Neurology · Portland area, OR
Neurology studies in Portland area, OR
42 recruiting studies have a site in the Portland area. This page includes nearby cities such as Beaverton, Hillsboro, Gresham, Tigard.
42 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Portland, OR + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 2
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Sanofi
- Location
- Portland, OR + 9 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Portland, OR + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Portland, OR + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Portland, OR + 67 other US sites
- Eligibility basics
- Ages 50–90
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Portland, OR + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Portland, OR + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Xenon Pharmaceuticals Inc.
- Location
- Portland, OR + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Portland, OR + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Portland, OR + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Portland, OR + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Portland, OR + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Portland, OR + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Portland, OR + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Tigard, OR + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Portland, OR + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Portland, OR + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Portland, OR + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Portland, OR + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Portland, OR + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Portland, OR + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Portland, OR + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Portland, OR + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Portland, OR + 39 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.